< Back to Article

Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study

Fig 5

The cumulative risk of re-presentation with P. vivax malaria by baseline risk factor.

A: primaquine dose category; B: P. vivax mono- or mixed infection; C: gender; D: ethnicity; E: age group; F: year; G: initial treatment as an outpatient or inpatient; H: vivax malaria episode number. (PQ, Primaquine; SD, Single Dose; LD, Low Dose; HD, High Dose).

Fig 5